Drug Trial Radar · NCT06097364
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
733
Planned (sponsor's estimate)
Start
Nov 14, 2023
Primary completion
Jul 29, 2029
Study completion Jul 29, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study. This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled). The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study. The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality-of-life and ability to complete routine daily activities
Conditions
- Follicular Lymphoma (FL)
Interventions
OdronextamabDrug
Administered by intravenous (IV) infusion
RituximabDrug
Administered by IV infusion, or subcutaneous (SC)
CyclophosphamideDrug
Administered by IV infusion
DoxorubicinDrug
Administered by IV infusion
VincristineDrug
Administered by IV infusion
Prednisone/PrenisoloneDrug
Administered orally (PO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapyTime frame: Up to 35 days
- Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapyTime frame: Up to 2 years
- Severity of TEAEs of odronextamab in combination with chemotherapyTime frame: Up to 2 years
- Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)Time frame: Up to 30 months
Locations
145 sites in 17 countries. Site status is shown where the registry gives one.
Boca Raton Clinical Research (BRCR) Global
Plantation, Florida
Investigative Clinical Research of Indiana
Noblesville, Indiana
Cancer Center of Kansas
Wichita, Kansas
University of Kentucky
Lexington, Kentucky
Henry Ford Health System
Detroit, Michigan
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan
Center for Oncology and Blood Disorders
Houston, Texas
Community Cancer Trials of Utah
Ogden, Utah
Prohealth Care Inc
Waukesha, Wisconsin
Liverpool Hospital
Liverpool, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
Universitatsklinik fur Kinder und Jungendheilkunde
Vienna, Austria
Klinikum Wels-Grieskirchen
Wels, Austria
Karl Landsteiner University Hospital St. Poelten
Sankt Pölten, Lower Austria, Austria
Medical University of Graz
Graz, Styria, Austria
Landeskrankenhaus Hochsteiermark
Leoben, Styria, Austria
Innsbruck Medical University
Innsbruck, Tyrol, Austria
Kepler University Hospital
Linz, Upper Austria, Austria
Institut Jules Bordet
Brussels, Belgium
Centre Hospitalier Regional de la Citadelle
Liège, Belgium
Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium
Verenigde Ziekenhuizen van Waas en Durme
Sint-Niklaas, Oost-Vlaanderen, Belgium
Algemeen Ziekenhuis St Jan Brugge Oostende Av
Bruges, West-Vlaanderen, Belgium
AZ Groeninge
Kortrijk, West-Vlaanderen, Belgium
Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil
AC Camargo Cancer Center
São Paulo, Brazil
Clinical Hospital of Medicine School at Sao Paulo University
São Paulo, Brazil
Casa de Saude Santa Marcelina
São Paulo, Brazil
Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
Salvador, Estado de Bahia, Brazil
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil
Ensino e Terapia de Inovacao Clinica Amo (Etica)
Salvador, Estado de Bahia, Brazil
Hospital Sirio Libanes Brasilia
Brasília, Federal District, Brazil
Instituto DOr de Pesquisa e Ensino Df Star
Brasília, Federal District, Brazil
Instituto Mario Pena de Ensino Pesquisa e Inovacao
Belo Horizonte, Minas Gerais, Brazil
Centro Oncologico do Triangulo (COT) - Uberlandia
Uberlândia, Minas Gerais, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
Liga Norte Riograndense Contra o Cancer
Natal, Rio Grande do Norte, Brazil
Instituto Tacchini de Pesquisa em Saude
Bento Gonçalves, Rio Grande do Sul, Brazil
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.